Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Asthma Healthy Volunteers Be a man or woman between 18 to 50 years of age, inclusive, at the time of signing the informed consent Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study If a woman of childbearing potential, must have a documented menstrual period prior to the first dose and be willing and able to use two forms of contraception from screening to 90 days after the final dose of RV1729, OR If a woman of non-childbearing potential must be amenorrhoeic for greater than 1 year or have been permanently sterilised, OR If a man, must be willing and able to use one of the contraception methods listed in the protocol and agree not to donate sperm, the first dose until 90 days after they receive the final dose of RV1729 Body mass index between 19 and 30 kg/m2 (inclusive), and body weight not less than 50 kg Vital sign assessments within normal ranges: blood pressure between 90 and 140 mmHg systolic, inclusive, and between 40 and 90 mmHg diastolic; heart rate 40 bpm Have a 12-lead ECG consistent with normal cardiac conduction and function Capable of complying with all study restrictions and procedures including ability to use the study Dry Powder Inhaler correctly Parts A & B (healthy volunteers only)  Upper or lower respiratory tract infection within 4 weeks of the screening visit Clinically significant abnormal values for haematology, clinical chemistry or urinalysis at screening History of, or a reason to believe a subject has a history of drug or alcohol abuse within the past 5 years Positive test for alcohol or drugs of abuse at screening or prior to dosing History of clinically significant allergies that would contraindicate participation Known allergy to the study drug or any of the excipients of the formulation Donated blood or blood products or had substantial loss of blood (more than 500 mL) within 3 months before the study Received an experimental drug or used an experimental medical device within 3 months or within a period less than 10 times the drug's half life before the first dose of the study drug is scheduled If a woman, has a positive serum pregnancy test at screening or on admission, is pregnant, breast-feeding or planning to become pregnant during the study Positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B virus (HBV) infection, or hepatitis C antibodies